Document 3KRX1JqLxRzVzEZNgRKboEqJ
scence rns
Comaron SRT ore
Ln
SE
wiaorigmisamcawascaem
4 \FT, STETTINIUS & HOLLISTER Lv.
amos
1800 FIRSTAR TOWER
425 WALNUT STREET
cn Gio n eae:
SiS
AR 226 - 1173 CINCINNATI, OHIO 45202-3957 e5a13S.318513.a2r03080s wo ttinncom
cokouissnsag
tre
March 8, 2002
TELECOPY AND
REGULAR U.S. MAIL
Donald S. Welch
UR.eSg.ioEnnavlirAdomnimneinsttarlatPorrotection Agency Region Ill
1650 Arch Street Philadelphia, PA 19103-2029
Janet E. Sharke, Esq, (3RC30)
U.S. Environmental Protection Agency Region Ill Office Of Enforcement, Compliance and
Environment Justice (Mail Code 3EC00)
1650Arch Street
Philadelphia, PA 19103-2029
Thomas V. Skinner Regional Administrator
US. Environmental Protection Agency Region V
77 West Jackson Blvd. Chicago, IL 60604
Kelley Moore (6-151)
US. Environmental Protection Agency Region V 77 West Jackson Blvd. Chicago, IL 60604
=
E on E35 a SR
= 5%
= 89
Re: Public Health Concemn Involving C- Drinking Water Contamination ln ~~ 1
West Virginia And Ohio
Ladies and Gentlemen:
As indicated in our November 1, 2001, letter to the United States EPA, ATSDR, and the
`West Virginia Department of Environmental Protection, our law firm is currently working with
two other law firms in West Virginia in the representationof numerous individuals who have `broughtaclass action lawsuit against E.I. duPont de Nemours and Company ("DuPont") and the
cLounbteacmkinPautbiloinc oSferhvuimceanDidsrtriincktiongf wWaotoerdsCuopupnltiyes, vWietshtaVmimrgoinniiau(m"LpPeSrfDl"u)orionoccotnannoeactteio(n2w/iath the AWePsFtO/VFirCg-in1i4a3./PAFcOoAp)y (o"fC-o8u"r)colireingtisn'atAimneg nfdreomd DCuoPmopnlta'isntWainshtihantgmtaotnteWrorprkesviionuWsloyowdasCounty,
forwarded to your agencies. As indicated in that Amended Complaint, our clients are concemed.
tchuartretnhterpereisseanccuerorfenet,xciemsmsiinveenlte,vealnsodfsCu-bs8tanitnialloctahlrdeartintkoitnhgeiwratheearlstuhpbpaliseesd. uWpoenhtahveepaasstkeadndthe
NTAIN NG cy
000054
March 8, 2002 Page2
Circuit Court in those who have
West Virginia to order, been exposed to C-8 in
among other their water.
things,
appropriate
medical
monitoring
for
It has come to our attention that your agency is in the process of finalizing a Consent OberednercownitthamDiunPaotendtwtiotphroCv-i8deorfiogrinaalttienmgatferowmatDeurPosunptp.liIetsatlosothhoassecwohmoesetodoruirnkaitntgwenattioenrthhaast your awagteenrcyunhlaesssnotthebeleevnelasbloef tCo-o8betaxicneeDduPao1n4t'pspbaglreeveelmeandtvotcoaitmemdediniaatJealnyuaprroyv2i4d,e 2a0n0y2,alrteepmoarttive prepared by DuPont's consultant, Environ.
As indicated in the attached document prepared by Tetra Tech, which has thoroughly reviewed the same information referenced and relied upon in DuPont's Environ report, our clients believe that the 14 ppb number selected by Environ is in error and substantially underestimates the potential health threat to those drinking C-8 contaminated water. The current data actually confirms that C-8 levels in excess of 03 ppb in human drinking water may present an imminent and substantial endangerment to human health and the environment. Thus, on behoafloufr clients, we request that your agency consider the issues raised in the attached document from Tetra Tech before agreeing to any Order with DuPont that does not require DuPont to immediately provide alterate drinkingwaterto those exposed to C-8 levels in excess of 0.3 ppb.
Please let us knowif you have any questions about anyofthe issues raised in the attached document. Thank you.
A (obert A. Bilott
RAB/mdm Attachment cei Amando Benincasa, Esq. (WVDEP)
Greg Smith, Esq. (Ohio EPA)
000055
March 7, 2002
Pagel
Tera Tech, nc.
DISCUSSION POINTS RELATING TO THE ASSESSMENT OF HEALTH RISK FROM EXPOSURE TO AMMONIUM PERFLUOROOCTANOATE (PFOA)
hThuemafnolhleoawlitnhgriissksfuoerspoarpeulcartiitiocnasletxopotsheeddetoveilnogepsmteendtPofFaOA.puTbhlei.cdihseaclutshsipornoitsepcatritviecualsasrelsysrmeelnevtaontf
N0aramnateivvaelufaotrioPneorffaluroercoeoncttaansosaetsesm(ePnFtoOAf)r.iskprteophauremdanbypopEunlvaitrioonnsIenxtpeomasteidontaolPFCoOrApo(raAtiHoanzafrodr
DuPont, January 24, 2002).
IL Relevance of the PFOA study in cynomolgus monkeys to human health risk assessment
The following issues relate o the interpretation ofa six-month study in cynomolgus monkeys dosed
with PFOA (Covance 6329-231, December 18, 2001). This study formed the basis for the calculation ofa drinking water criterion proposed in DuPont's Environreport.
A. Severity of the endpoint
Severe toxicity was reported in the cynomolgus. monkey study. The use of severe
tEoPxiAciptryacatsiacenseannddpoiisnntotfardoemquwahtieclhy
to calculate safety levels is
protectiveofpublic heath.
not consistent with
A critical endpoint
thcaytncoomuolldgubse muosnedkequyansttiutdya.tively in development of an RD was not identified in the
B. Mode or mechanism of action
p`Trhiemamtoedsemoornkmeecyhsahnaissnmootfbaecetinornepfoorrtetdh.e sTehveerelatcokxiocfistuycehxhiinbfiotremdabtyiotnhelenaovnehsuompaenn
the
atd
possibilit
ose levels
y that
much
as yet undiscovered
below those used in
effects specific to primates may
this cynomolgus monkey study,
be occurring
adding great
uncertainty to any assessment of human health risk.
C. Humans may be an especially sensitive species
Rats tolerate PFOA toxicity better than monkeys and monkeys may eliminate PFOA more efficiently than humans. Since elimination of PFOA is a major factor in
PtdheFetOesrAammitneoixinccrgsiittpiyeccatliheaesnndidafpnfoyeironefttnhcaeses einxnoptenorxhiiumcmernaetnsaplopnrasinemi,amthaeulsmmamonadsey,lswb.heicthhemmoostrelikseelnysiptoisvseestso
D. The absorbed PFOA dose in the monkey study may be in question
There is evidence that PFOA is not well absorbed in the rat gut. There may also
have been
possibility
poor absorption
of these effects
in
is
the gut with possible
a further uncertainty
emesis
in extr
in the.
apolat
monkey
ing to hu
study.
mans.
The
000056
1
March 7,2002
Page2
IL. Drinking Water Criterion Calculation
Tera Tech, Inc.
Sshaufeedfiossrshuhoeuuslmddaennsoctcriobbneesdusmeapbdtoiavosne.trheeTgpahrrediimmnaogrnytkhbeeaysPssFtiOundAdyessrthiuovduiylndgi,anlecvyenlomooflgPuFsOAmomnkderyisnkiinndgicwaatveesthaatthe sfEotpruidhyupmiranondcsei.dcuartIeiasna,gchnreoendicforraat svetruydycoisnsseervdattiovdeeraipvperoaascahfetoltehhvoeewldeovefeevrxe,plobsoeupcrmoenesionnifdtdse.rariefndkei3esnxugppwopasltueermreeunlsetivanegll fuascitnogr aobefnc0.2.hmarkaddorsienkriensg:pownastee,racnriutnecreirotnaoifntnyofhiaghecorftt3h0a,on000r.03, paanrdsapreerlabtiilvleionu(speessae pseurree.s
HL Assessment of Cancer Risk
dWiunheiadltdeoibttiiiooncnh0oetmucimlceoaalrrsdwoihffeftethhreeenrlciPevseFrbO,erAotdwieennedtnuscrdeooddsetenudtmsowriastnhdoPfhtuFhmOeaAnlisev,exrhiobcictutreisntiecxulpaorsaenddHpaamncarnepaotpiuclmatoironss
catohsnessetiswdseomretanettshtiiescusuilntakersntouawmreonr.dsi,fIfneraecnctotrhdaanncfeorwtihteh rtohdeernetcloimvmerenadnadtttihhoeenimsrerocehlafaennvaiensxcmpeeortftoahpcatunimoenalncohpmemuaennlceeopuvys
ainsskibaustsaebslsemteontPFinOhAeexapbosseuntrceeesottiofcurelovadiredtneutnsmcoserhsotouslhtdoheuallcsdoonbtbereacrocyon.nssiidFdeoerrresedidmlaielglaiertgiirmteaiatmseaotenens,depnpodaipnnotirsnetfaonrc acnarerrery
risk assessment.
for cancer
000057